Evidence map›Paper›PMID 42058285›Full record

ArticleBlood neoplasia2026

Outcomes of hemophagocytic lymphohistiocytosis in acute myeloid leukemia: the 3-site Mayo Clinic experience.

Jabra Zarka, Clifford M Csizmar, Syeda Mina, Ashley Hickman, Erica Andres, Aasiya Matin, Naseema Gangat, Talha Badar, Abhishek A Mangaonkar, Mrinal M Patnaik and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Jabra ZarkaDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Clifford M CsizmarDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Syeda MinaDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Ashley HickmanDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Erica AndresDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Aasiya MatinDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Naseema GangatDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Talha BadarDivision of Hematology/Oncology, Mayo Clinic, Jacksonville, FL.
Abhishek A MangaonkarDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Mrinal M PatnaikDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Mark R LitzowDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
William J HoganDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Mehrdad Hefazi TorghabehDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
James M ForanDivision of Hematology/Oncology, Mayo Clinic, Jacksonville, FL.
Cecilia Arana YiDivision of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ.
Mithun V ShahDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Kebede H BegnaDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Aref Al-KaliDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Hassan B AlkhateebDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Antoine N SalibaDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a rare but fatal complication of acute myeloid leukemia (AML), and contemporary data on its clinical and genomic correlates remain sparse. We retrospectively identified 19 adults with AML who developed HLH across 3 Mayo Clinic sites (2020-2024) and compared them with 73 patients with AML without HLH. HLH occurred at a median of 34 days from AML diagnosis (range, 0-472) and was associated with fever, multiorgan dysfunction, and rapidly rising biomarkers. Morphologic hemophagocytosis was observed in only 18% of cases, underscoring its poor sensitivity. HLH was associated with markedly inferior overall survival (median, 5.7 vs 14.8 months,

Identifiers

PMID42058285
PMCPMC13123359

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.